TNX-103 Clinical Trials
2 recruitingDrug
Phase 32
Showing 1–2 of 2 trials
Recruiting
Phase 3
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398
Recruiting
Phase 3
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Pulmonary Hypertension
Tenax Therapeutics, Inc.230 enrolled44 locationsNCT05983250